A payer consistently denies claims for a specific high-cost drug citing 'experimental or investigational.' The drug has FDA approval. What is the strongest appeal argument?
-
A
The drug's wholesale acquisition cost is lower than alternatives
-
B
The drug has received full FDA approval and meets evidence-based clinical guidelines for the diagnosis
-
C
The patient prefers this drug over alternatives
-
D
The provider is an academic medical center